Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation

  • Epigenetics. 2012 Apr;7(4):340-3. doi: 10.4161/epi.19506.
Glenn S Van Aller  1 ,  Nicolas Reynoird ,  Olena Barbash ,  Michael Huddleston ,  Shichong Liu ,  Anne-Flore Zmoos ,  Patrick McDevitt ,  Robert Sinnamon ,  BaoChau Le ,  Gloria Mas ,  Roland Annan ,  Julien Sage ,  Benjamin A Garcia ,  Peter J Tummino ,  Or Gozani ,  Ryan G Kruger
Affiliations
  • 1. GlaxoSmithKline, Collegeville, PA, USA.
PMID: 22419068 DOI: 10.4161/epi.19506
Abstract

SMYD3 is a lysine methyltransferase implicated in chromatin and Cancer regulation. Here we show that SMYD3 catalyzes histone H4 methylation at lysine 5 (H4K5me). This novel histone methylation MARK is detected in diverse cell types and its formation is attenuated by depletion of SMYD3 protein. Further, Smyd3-driven Cancer cell phenotypes require its enzymatic activity. Thus, SMYD3, via H4K5 methylation, provides a potential new link between chromatin dynamics and neoplastic disease.